![](https://assets.foleon.com/eu-west-2/uploads-7e3kk3/6245/cfounder.56411b6ad257.png)
Current Leadership:
Esra Saraçoğlu, General Manager
Founding Year: 1999
![](https://assets.foleon.com/eu-west-2/uploads-7e3kk3/6245/timeline.d016ce7217bb.png)
![](https://assets.foleon.com/eu-west-2/uploads-7e3kk3/6245/rd.7c5b8c38b176.png)
R&D
R&D focus
Platin Kimya is going to run its own contemproray R&D laboratory in March 2020.
![](https://assets.foleon.com/eu-west-2/uploads-7e3kk3/6245/export.9b29116bd674.png)
Exports
Export % in revenues:
15%
List of export countries:
Russia, Azerbaijan, Kazakhistan, China
In More Depth
Number of employees
Platin Kimya has 150 and Platin Pharma has 15 people Revenue or Growth Rate in past financial year:
50m $USD as Platin Kimya USP/ or a differentiating fact:
We are the first company to patent Zoledronic Acid 5mg/100m in the Turkish market.
Partnerships
We are also working on establishing partnerships for new molecule and formulation worldwide. Prominent partnerships/clients
Our main PARTNESHIP Abdi Ibrahim for CMO and Orna ilac for Sales&Marketing rights for Onzyd. Establish new partnership for new molecule and formulation in worldwide as well.
![](https://assets.foleon.com/eu-west-2/uploads-7e3kk3/6245/untitled-2.4be5a43bc072.jpg)